JEQUED
DEAD

Serial Number

90271685

Owner

BRISTOL-MYERS SQUIBB COMPANY

Attorney

Marilyn F. Kelly

Filing Date

Oct 22, 2020

Add to watchlist:

No watchlists yet
View on USPTO

JEQUED Trademark

Serial Number: 90271685

JEQUED is a trademark filed by BRISTOL-MYERS SQUIBB COMPANY on October 22, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

BRISTOL-MYERS SQUIBB COMPANY (4,799 trademarks)

NEW YORK, NY 10154

Entity Type: 03

Trademark Details

Filing Date

October 22, 2020

Registration Date

Not Registered

Published for Opposition

September 14, 2021

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for use in disease testing

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Dec 16, 2024 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Dec 16, 2024 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 6, 2024 EXRA
SOU EXTENSION 5 GRANTED
Apr 5, 2024 EX5G
SOU EXTENSION 5 FILED
Apr 5, 2024 EXT5
SOU TEAS EXTENSION RECEIVED
Apr 5, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 14, 2023 EXRA
SOU EXTENSION 4 GRANTED
Oct 12, 2023 EX4G
SOU EXTENSION 4 FILED
Oct 12, 2023 EXT4
SOU TEAS EXTENSION RECEIVED
Oct 12, 2023 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 2, 2023 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 2, 2023 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 2, 2023 COAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 28, 2023 EXRA
SOU EXTENSION 3 GRANTED
Apr 26, 2023 EX3G
SOU EXTENSION 3 FILED
Apr 26, 2023 EXT3
SOU TEAS EXTENSION RECEIVED
Apr 26, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 4, 2022 EXRA
SOU EXTENSION 2 GRANTED
Nov 2, 2022 EX2G
SOU EXTENSION 2 FILED
Nov 2, 2022 EXT2
SOU TEAS EXTENSION RECEIVED
Nov 2, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 7, 2022 EXRA
SOU EXTENSION 1 GRANTED
May 5, 2022 EX1G
SOU EXTENSION 1 FILED
May 5, 2022 EXT1
SOU TEAS EXTENSION RECEIVED
May 5, 2022 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 9, 2021 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 14, 2021 NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 14, 2021 NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 14, 2021 NPUB
PUBLISHED FOR OPPOSITION
Sep 14, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 26, 2021 NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 26, 2021 NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 26, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 6, 2021 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 6, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 6, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 6, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 6, 2021 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 28, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 27, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 27, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 29, 2021 GNRN
NON-FINAL ACTION E-MAILED
Jan 29, 2021 GNRT
NON-FINAL ACTION WRITTEN
Jan 29, 2021 CNRT
ASSIGNED TO EXAMINER
Jan 27, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 10, 2020 NWOS
NEW APPLICATION ENTERED
Oct 26, 2020 NWAP